1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market

  • June 2014
  • 72 pages
  • Frost & Sullivan
Report ID: 2200861

Summary

Table of Contents

Relentless Pursuit of Blockbuster Cardiovascular Therapeutics

Dyslipidemia exists in many forms and is prevalent in developed regions. Although many patients with moderately elevated lipids are well served by available therapies, there is a significant patient population for whom these therapies are inappropriate or inadequate, thereby prompting development of innovative therapies to fill the gaps. This research service includes comprehensive information on the market background, analyses of drug development, detailed product and pipeline analyses, detailed product profiles for key marketed/late-stage products, and a global overview. The research service also provides time-sensitive details such as new product launch timelines, PCSK9 Phase 3 programs, and patent expirations.

Executive Summary

-Most therapeutic lipid modulators in development are targeting the unmet needs of patients with high lipid levels beyond the reach of available drugs.
-The market is experiencing a tight race between 3 members of a promising new drug class: Inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9).
oAmong the close competitors in the PCSK9 race, Amgen is currently the front runner, with an expected filing for regulatory approval of evolocumab planned in 2014. Sanofi and Regeneron are approximately to months behind, with regulatory filing of alirocumab planned for 2015. Pfizer is potentially filing bococizumab in 2016.
oAll 3 PCSK9 Phase 3 programs include a cardiovascular outcomes trial (CVOT) of approximately to patients.
oAmgen’s Phase 3 program for evolocumab is the largest of the competitors, including over patients across clinical trials, one of which is evaluating the drug’s effect on atherosclerotic plaque through an intravascular ultrasound.
oThe Sanofi/Regeneron Phase 3 program for alirocumab is nearly as extensive, with over patients enrolled across trials.
oPfizer’s Phase 3 program for bococizumab includes over patients enrolled across trials, with of those trials evaluating the effect of bococizumab on cardiovascular outcomes.
-Other targets of drugs in development include cholesteryl ester transfer protein (CETP), liver X receptor (LXR), peroxisome proliferator-activated receptor delta (PPAR?), and diglyceride acyltransferase (DGAT), among several additional novel targets.
-New clinical guidelines for cholesterol management released by the American Heart Association (AHA) and the American College of Cardiology (ACC) focus on treating with statins according to a cardiovascular risk profile, as opposed to treating to a specified low-density lipoprotein cholesterol (LDL-C) target. While these new recommendations have the potential to widen significantly the statin-appropriate population, clinicians may be slow to change practice.
oSimilar recommendations were recently announced in the United Kingdom.
-Among the recently approved and late-stage lipid-lowering drugs such as mipomersen, lomitipide, and PCSK9 inhibitors, none will replace statin therapy for the general hyperlipidemic population in the foreseeable future. However, these drugs may be useful as adjunctive therapies, as statin alternatives for statin-intolerant patients, or for special populations for which statins are inadequate.

Methodology and Scope

-This research service focuses on prescription drugs to manage primary and secondary forms of dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia. This service does not include prescription medical foods or over-the-counter supplements.
-A product and pipeline assessment is provided for marketed and investigational drugs for the management of dyslipidemia. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
-The information contained in this research service was derived from published sources, including the following: disease organization Web sites; public health organization Web sites; company publications such as annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Arteriosclerosis Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • April 2017
  • by GlobalData

Arteriosclerosis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Arteriosclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Arteriosclerosis ...

Ezetimibe / Simvastatin Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Ezetimibe / Simvastatin Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Ezetimibe / Simvastatin worldwide and by countries in North America, ...

Atorvastatin / Ezetimibe Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Atorvastatin / Ezetimibe Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Atorvastatin / Ezetimibe worldwide and by countries in North ...


Download Unlimited Documents from Trusted Public Sources

Global Lipid Modifying Drug Market - Forecast

  • June 2017
    3 pages
  • Lipid Modifying...  

    Therapy  

    Cardiovascular ...  

  • United States  

    Europe  

    World  

View report >

Lipid Modifying Drug and Therapy Market in the US

  • April 2017
    24 pages
  • Statins  

    Therapy  

    Lipid Modifying...  

  • United States  

    World  

View report >

Lipid Modifying Drug Market in the US

  • March 2017
    10 pages
  • Lipid Modifying...  

  • United States  

View report >

Related Market Segments :

Lipid Modifying Drug

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.